KIDNEY CANCER: A LITERATURE REVIEW

Authors

  • João Vitor Dias Calzada Médico pela Universidade Federal do Mato Grosso (UFMT)
  • Tharleton Ribeiro de Souza Graduando em Medicina pela Universidade de Rio Verde (UniRV)
  • Thifisson Ribeiro de Souza Graduando em Medicina pela Universidade de Rio Verde (UniRV)
  • Nertan Ribeiro Batista Graduando em Medicina pela Universidade Federal de Campina Grande (UFCG)
  • Fernanda Cunha Alves Médica pela Universidade de Rio Verde (UniRV)
  • Igor Ferreira Partata Médico pela Afya Palmas
  • Sara Mendonça Chahla Médica pela Universidade Federal de Ouro Preto (UFOP)
  • Kayro Breder Catta Preta Leal Médico pela Universidade Federal do Rio de Janeiro (UFRJ)

DOI:

https://doi.org/10.36557/pbpc.v3i2.206

Keywords:

Kidney Neoplasms; Risk Factors; Genetics.

Abstract

This narrative literature review gathered articles published in the last 5 years in PUBMED with the aim of identifying the risk factors related to the development of kidney cancer. Kidney cancer, especially renal cell carcinoma, is a neoplasm with multifactorial etiology. Genetic factors, such as hereditary mutations (e.g., in von Hippel-Lindau and Birt-Hogg-Dubé syndromes) and family history, significantly increase the risk of developing this disease. Environmental factors, such as smoking, exposure to chemical substances (e.g., trichloroethylene), and obesity, also contribute to renal carcinogenesis. Arterial hypertension, either due to the condition itself or to the prolonged use of certain antihypertensive drugs, is another important risk factor. Behaviors such as a diet rich in saturated fats and low in fiber, excessive alcohol consumption, and a sedentary lifestyle also increase the risk of kidney cancer. In addition, sex hormones, especially in women on hormone replacement therapy, can influence the development of the disease. Effective prevention and management of kidney cancer depends on modifying these risk factors and monitoring genetically predisposed individuals. Strategies such as promoting healthy habits and medical follow-up are crucial to reducing the incidence of the disease.

References

ALAGHEHBANDAN, R.; SIADAT, F.; TRPKOV, K. What's new in the WHO 2022 classification of kidney tumours? Pathologica; v. 115, n. 1, p. 8-22, 2022.

AMARO, F. et al. Metabolic signature biomarkers for predicting the recurrence of urological cancers. Clin Chim Acta; 549:117553, 2023.

BAHADORAM, S. et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol; 2022, 39(3): 2022-vol3, 2022.

BRASIL. Lei Nº 12.853. Brasília: 14 de agosto de 2013. Acesso em 01 de novembro de 2023.

CALIÒ, A. et al. WHO 2022 Classification of Kidney Tumors: what is relevant? An update and future novelties for the pathologist. Pathologica; v. 115, n. 1, p. 23-31, 2022.

LI, F. et al. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J Exp Clin Cancer Res; v. 40, n. 1, p. 254, 2021.

LJUNGBERG, B. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol; v. 82, n. 4, p. 399-410, 2022.

MOTZER, R.J. et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw; v. 20, n. 1, p. 71-90, 2022.

MOTZER, R.J. et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw; v. 18, n. 9, p. 1160-1170, 2020.

TAKEMURA, K. et al. Trends in health care spending on kidney cancer in the United States, 1996-2016. Cancer; v. 129, n. 14, p. 2161-2168, 2023.

TRPKOV, K. et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol; v. 34, n. 6, p. 1167-1184, 2021.

VILAR, L. Endocrinologia Clínica. 7. ed. Rio de Janeiro: Grupo GEN: Guanabara Koogan, 2020.

Downloads

Published

2024-08-25

Issue

Vol. 3 No. 2 (2024): PBPC 2024

Section

Ciências da Saúde

License

Copyright (c) 2024 João Vitor Dias Calzada , Tharleton Ribeiro de Souza , Thifisson Ribeiro de Souza , Nertan Ribeiro Batista , Fernanda Cunha Alves, Igor Ferreira Partata, Sara Mendonça Chahla , Kayro Breder Catta Preta Leal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Você tem o direito de:

  1. Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
  2. Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
  3. O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.  

 

De acordo com os termos seguintes:

  1. Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
  2. Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.